Table 1

Demographic data of all PREVENT-JIA participants that were recruited at six centres

CharacteristicsAll patients recruited
Female, No. (%)81 (69)
Male, No. (%)37 (31)
Age at disease onset, median (range), years6.0 (<1–15.0)
Duration from therapy start to inactive disease, median (range), years1.6 (<1–11.8)
Age at I1, median (range), years10.3 (3.0–17.5)
Disease duration at I1, median (range), years3.3 (<1–15.3)
JIA subtype, No. (%)
 Oligoarthritis (extended)25 (21)
 Polyarthritis, negative rheumatoid factor70 (59)
 Polyarthritis, positive rheumatoid factor3 (3)
 Systemic-onset juvenile idiopathic arthritis4 (3)
 Enthesitis-related arthritis6 (5)
 Psoriasis arthritis8 (7)
 Other2 (2)
Final therapy, No. (%)
 csDMARD, no bDMARD91 (77)
 bDMARD ± csDMARD27 (23)
  • bDMARD, biological DMARD; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; JIA, juvenile idiopathic arthritis ; MTX, methotrexate.